title: Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial.
abstract: BACKGROUND
  Cardiac magnetic resonance imaging (CMR) can accurately determine infarct size. Prior studies using indirect methods and CMR to assess infarct size have shown that patients with larger myocardial infarctions have worse prognoses. Implantable cardioverter defibrillators (ICD) have been shown to improve survival among patients with severe left ventricular (LV) dysfunction. However, the majority of cardiac arrests occur in patients with higher ejection fractions.
  
  
  METHODS
  The Defibrillators To Reduce Risk By Magnetic Resonance Imaging Evaluation study (DETERMINE) is a prospective, multicenter, randomized, clinical trial in patients with coronary artery disease (CAD) and mild-to-moderate LV dysfunction. The purpose of this trial is to test the hypothesis that patients with an infarct size > or = 10% of LV mass, randomized to ICD plus appropriate medical therapy will have improved survival compared with patients randomized to medical therapy alone. Cine and myocardial delayed contrast CMR will be performed in patients with CAD. The primary endpoint will be death from any cause. At least 10,000 patients with CAD will undergo CMR. The target enrollment is 1,550 patients with an estimated 36-month enrollment period. The patients will be followed up for 24 months after the last patient randomization. During the follow-up period, 330 deaths are estimated to occur. This study is powered to detect a 28% reduction in mortality by ICD therapy.
  
  
  CONCLUSIONS
  The DETERMINE trial will assess the efficacy of ICD therapy to improve survival among patients with CAD, mild-to-moderate LV dysfunction, and infarct size > or = 10% of LV mass as measured by CMR.
authors.affiliation: Division of Cardiology, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA. a-kadish@northwestern.edu
authors.forename: Alan H
authors.initials: AH
authors.lastname: Kadish
authors.forename: David
authors.initials: D
authors.lastname: Bello
authors.forename: J Paul
authors.initials: JP
authors.lastname: Finn
authors.forename: Robert O
authors.initials: RO
authors.lastname: Bonow
authors.forename: Andi
authors.initials: A
authors.lastname: Schaechter
authors.forename: Haris
authors.initials: H
authors.lastname: Subacius
authors.forename: Christine
authors.initials: C
authors.lastname: Albert
authors.forename: James P
authors.initials: JP
authors.lastname: Daubert
authors.forename: Carissa G
authors.initials: CG
authors.lastname: Fonseca
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Goldberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000401:mortality* / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data*; D004554:Electric Countershock / Q000401:mortality*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011379:Prognosis; D018570:Risk Assessment; D040242:Risk Reduction Behavior; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D018487:Ventricular Dysfunction, Left / Q000401:mortality* / Q000517:prevention & control*